Mer Scott
Quiz by , created more than 1 year ago

PHCY310 Quiz on L16 Therapeutics of Asthma, created by Mer Scott on 12/04/2019.

8
0
0
Mer Scott
Created by Mer Scott over 5 years ago
Close

L16 Therapeutics of Asthma

Question 1 of 8

1

Clinical practice guidelines, meta-analysis, and systematic reviews are the highest ranked forms of evidence.

Select one of the following:

  • True
  • False

Explanation

Question 2 of 8

1

Māori are 3.4 times, and Pacific peoples 3.9 times, more likely to be admitted to hospital with asthma than Europeans or other New Zealanders.

Select one of the following:

  • True
  • False

Explanation

Question 3 of 8

1

When diagnosing asthma there is no single “gold standard” test, and we must assess the pattern of (wheezing, breathlessness, chest tightness, and coughing, particularly at or in the morning). We can also measure on more than one occasion, and assess to inhaled bronchodilator +/- inhaled corticosteroid.

Drag and drop to complete the text.

    signs and symptoms
    night
    early
    expiratory airflow
    response

Explanation

Question 4 of 8

1

Ideal PEFR values depend on height and sex.

Select one of the following:

  • True
  • False

Explanation

Question 5 of 8

1

Which of these is NOT a principle of asthma treatment?

Select one of the following:

  • Avoid triggers

  • Making an asthma plan

  • Drugs to improve ventilation

  • Drugs to decrease inflammation

  • Avoid exercise

Explanation

Question 6 of 8

1

Goals of asthma treatment are about maintaining long-term control using the amount of medications and adverse effects.
We want to prevent chronic , require infrequent use ( or fewer days/week) of SABA, maintain normal or near-normal function and maintain levels. We should assure patients’ and families’ with asthma care. We also want to prevent exacerbations, the need for , and prevent progressive of lung function.

Drag and drop to complete the text.

    least
    minimising
    symptoms
    2
    pulmonary
    activity
    satisfaction
    hospitalisation
    loss

Explanation

Question 7 of 8

1

Which of these is not a drug delivery device?

Select one of the following:

  • Soft mist inhaler (SMI) - only with LAMA products in NZ

  • Nebuliser

  • Dry power inhaler (DPI)

  • Metered-dose inhaler (MDI) - spacer chamber

  • Dry mist inhaler (DMI)

Explanation

Question 8 of 8

1

Treatment steps:
1. At initial diagnosis, all patients should use a , as required..
2. Add an if patients have symptoms for more than weeks. Often a big decision! (The usual dose in adults is /day.)
3. If control is not adequate, can be increased.
4. If control is not adequate, combine . ( can be used as a preventer and replace SABA.)

Patients can step up or down in order to achieve and maintain control.
Check adherence and inhaler at each step of the way!

Drag and drop to complete the text.

    SABA
    ICS
    two
    budesonide 400 mcg
    ICS dose
    ICS with a LABA
    Formoterol+budesonide
    technique

Explanation